Sharemaestro Newsreel

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported strong Q2 2026 results, with net product revenue of $25.1 million and total revenue of $40.1 million. The company secured $75 million in non-dilutive royalty financing and a $15 million milestone payment, extending its cash runway into the second half of …

Septerna president & COO Elizabeth Bhatt disposes of $1.1m in stock

Elizabeth Bhatt, President and COO of Septerna, Inc. (NASDAQ:SEPN), sold 25,000 shares of common stock for $1.1 million on August 11, 2026, after acquiring them through stock option exercises. These transactions were executed under a Rule 10b5-1 sales plan, leaving Bhatt with 174,209 directly …

Tempest Therapeutics Q2 loss narrows to $5.2m; advances CAR-T pipeline

Tempest Therapeutics reported a Q2 2026 net loss of $5.2 million, a significant narrowing from the previous year, primarily due to reduced R&D expenses. However, year-to-date losses widened to $32.9 million, influenced by a $22.1 million charge for acquired in-process R&D. The company is …

REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on

Kirby McInerney LLP has filed a securities fraud class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made misleading statements regarding the Biologics License …

Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On?

Jade Biosciences (JBIO) recently released its Q2 2026 results, reporting a net loss of $55.77 million. Despite strong year-to-date share price returns of 63.91% and a 1-year total shareholder return of 216.64%, the stock's 90-day return declined, and it trades well below the average …

H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55

H.C. Wainwright has reiterated its Buy rating for Jade Biosciences (JBIO.US), keeping the target price at $55. This indicates continued confidence in the company's performance and future prospects from the analyst firm.

ImmuCell (NASDAQ:ICCC) Announces Earnings Results, Beats Estimates By $0.15 EPS

ImmuCell (NASDAQ:ICCC) reported its earnings results, beating the consensus estimate by $0.15 EPS with reported earnings of $0.20 per share. The biotechnology company also surpassed revenue expectations, bringing in $7.19 million against an anticipated $5.40 million. Despite these positive financial results, the company maintains …

AXSM|Axsome Therapeutics Inc|Price:213.630|Chg%:-1.030

Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?

On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte's INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme's proprietary ENHANZE drug delivery technology, …

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?

On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2α inhibitor) with Summit's ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of …

Fortress Biotech (NASDAQ:FBIO) Posts Earnings Results, Beats Estimates By $0.12 EPS

Fortress Biotech (NASDAQ:FBIO) announced its quarterly earnings, reporting an adjusted loss of $0.08 per share, surpassing the consensus estimate by $0.12. The biopharmaceutical company also exceeded revenue forecasts with $18.72 million. Despite mixed analyst sentiment and a "Hold" consensus rating, institutional investors own a …

Cibus (NASDAQ:CBUS) Releases Earnings Results

ADCT|ADC Therapeutics SA|Price:1.050|Chg%:-0.180

Kura Oncology (KURA) Stock Revenue Growth Clashes With Mounting Losses

Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?

Arcus Biosciences reported Q2 2026 results with $41 million in revenue and a $91 million net loss, along with new full-year revenue guidance. The stock has seen significant price returns (16.07% in 90 days, 24.35% YTD), and a current valuation suggests it is 24% …

Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock

Denali Therapeutics (NASDAQ:DNLI) insider Alexander Schuth sold 2,857 shares of the company's stock for approximately $71,625, reducing his position by 1% while still holding over 281,000 shares. Despite the company missing analysts' EPS estimates with a quarterly loss of $0.68 per share, revenue exceeded …

Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $71

Stifel has reiterated its Buy rating for UniQure NV (QURE.US), maintaining its target price at $71. This indicates continued confidence from Stifel in the company's stock performance.

Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results, Beats Expectations By $0.08 EPS

Caribou Biosciences (NASDAQ:CRBU) reported a quarterly loss of $0.24 per share, surpassing analyst expectations by $0.08, though revenue of $1.50 million fell short of estimates. Following the announcement, shares declined by 5.3% to $1.61. Despite substantial losses and a negative net margin, institutional investors …

Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis

Barclays PLC has filed an amended Schedule 13G, disclosing a 3.17% beneficial ownership stake in Zentalis Pharmaceuticals Inc. (ZNTL), totaling 2,263,328 shares as of June 30, 2026. This filing indicates that Barclays now holds 5 percent or less of the class. The ownership includes …

Akari Therapeutics Q2 Results: Net loss widens to $4.8 million

Akari Therapeutics reported a net loss of $4.8 million for Q2 2026, widening from $1.9 million year-over-year, primarily due to increased R&D expenses as it advances its lead ADC candidate, AKTX-101, towards mid-2027 Phase 1 trials. The company strengthened its financial position by raising …

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …

Stocks See Support from Favorable PPI Report

The S&P 500 Index ($SPX) (SPY) is up +0.57%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.22%. September E-mini S&P futures (ESU26) are up +0.58%, and September E-mini Nasdaq futures (NQU26) are …

Omeros (OMER) Stock Jumps On YARTEMLEA Profit Breakthrough

Quantinuum (QNTM) Stock Wrestles With IPO Charge After Revenue Jump

Alpha Cognition (NASDAQ:ACOG) Announces Quarterly Earnings Results

Capricor Therapeutics (NASDAQ:CAPR) Posts Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Belite Bio outlines February 12, 2027 PDUFA date for Tinlarebant in Stargardt disease following FDA priority review acceptance

Earnings Call Insights: Belite Bio (BLTE) Q2 2026 MANAGEMENT VIEW * Dr. Tom Lin (Chairman of the Board of Directors & CEO) framed the quarter around U.S. regulatory timing, saying, "the FDA has accepted our new drug application for Tinlarebant with priority review and …

Capricor outlines BLA amendment plan as FDA signals willingness to review, with PDUFA date set for August 22

Earnings Call Insights: Capricor Therapeutics (CAPR) Q2 2026 MANAGEMENT VIEW * Linda Marbán (Co-Founder, President, CEO & Director) said the company’s Deramiocel BLA “remains under review with the FDA with a current PDUFA target action date of August 22,” and framed updates around “our …

Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Tarsus Pharmaceuticals stock has delivered a very large 3 year return, yet the broader valuation checks still suggest it trades on the cheap …

Form 8K Ovid Therapeutics Inc For: 13 August By Investing.com

This article announces that Ovid Therapeutics Inc. filed a Form 8K on August 13. The brief notice from Investing.com indicates that the filing is available for review, with the company's stock symbol OVID mentioned alongside a slight positive change.

NovaBridge Biosciences to report H1FY26 results on Aug 20

NovaBridge Biosciences (NASDAQ: NBP) will hold a webcast on August 20, 2026, to discuss its financial results for the first half ended June 30, 2026, and provide a corporate update. The company, focused on oncology and ophthalmology programs, will host the webcast at 9:00 …

Insider Selling: Korro Bio (NASDAQ:KRRO) Director Sells $29,916.28 in Stock

Korro Bio (NASDAQ:KRRO) director Jean Francois Formela sold 2,143 shares of the company's stock for $29,916.28 on August 11th, reducing his holdings by 1.45% to 145,937 shares. This sale is part of a pattern of recent insider selling by Formela, including significant transactions in …

Celcuity (CELC) Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying Opportunity

Celcuity (CELC) has received FDA approval for REVTORPYK for certain metastatic breast cancer patients and its inclusion in NCCN guidelines. Despite this positive news, the stock has experienced a significant pullback, falling 22% over 30 days and 37.1% over 90 days. Analysts currently value …

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%

Xenon Pharmaceuticals (XENE) Insider Sells 10,000 Shares; Direct

Director Steven Gannon of Xenon Pharmaceuticals (XENE) sold 10,000 shares for $64.06 per share, totaling $640,600, reducing his direct holdings to 1,870 shares. This sale contributes to a broader trend of 13 insider sells and no buys over the past year at Xenon, signaling …

Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results